In summary, our data demonstrate that the combination of gilteritinib and mitoxantrone-liposomes substantially improves the survival of FLT3-ITD AML xenograft model mice compared to a single-drug or DMSO treatment and supports the clinical application of this therapeutic option as a novel approach for leukemia treatment. Here, FLT3 is linked to leukemia.